The NO receptor, NO-sensitive guanylyl cyclase, plays a key role in the NO/cGMP signal-transduction cascade. Two isoforms of the enzyme are currently known, the widely distributed vascular ␣ 1 ␤ 1 isoform and the neuronal ␣ 2 ␤ 1 isoform predominantly expressed in brain. Interaction with the PSD-95 (postsynaptic density protein-95) family of scaffolding proteins targets the neuronal ␣ 2 ␤ 1 isoform to synaptic membranes. The NO sensor of the guanylyl cyclase is formed by the prosthetic haem group, where NO binding takes place and induces the up to 200-fold activation of the enzyme. The haem group allows tight regulation of enzymic activity by NO and represents the most striking feature of the enzyme, as it differs in many aspects from the well-characterized haem groups of other haemoproteins. The new NO sensitizers such as YC-1 [3-(5Ј-hydroxymethyl-2Ј-furyl)-1-benzylindazole] affect activation by NO and CO by mechanisms that are currently subject to intense research.
Introduction
Since the 19th century, explosive nitroglycerin has been known to be effective in the treatment of angina pectoris and the most prominent patient receiving this medication was Alfred Nobel, the inventor of dynamite (kieselguhr-stabilized nitroglycerin). Nearly a century later it became clear that administered nitroglycerin releases the labile gas NO, which stimulates the cGMP-forming GC (guanylyl cyclase), thereby causing smooth muscle relaxation. It took some more years to find out that NO is also produced within the body, acting as a messenger molecule involved in processes like smooth muscle relaxation, inhibition of platelet aggregation and neurotransmission.
Most of the effects of NO as a signalling molecule are mediated by the unusual haemoprotein GC, which plays a key role in the NO/cGMP-mediated signal-transduction cascade. This NO receptor together with the peptide receptor GCs constitute the superfamily of cGMP-forming cyclases, which generate cGMP from GTP. cGMP exerts its effects by binding to cGMP-regulated phosphodiesterases, cGMP-dependent protein kinases and cGMP-regulated ion channels. The review will summarize new information on NO-sensitive GC with a special focus on the mechanism of activation by NO and new stimulators.
Isoforms Subunit composition
The heterodimeric NO-sensitive GC is composed of two different subunits, ␣ and ␤, and a prosthetic haem group, which will be discussed below. The enzyme (␣ 1 ␤ 1 ) was initially purified from lung tissue and both subunits have been cloned and sequenced 15 years ago [1] [2] [3] [4] . Due to several sequencing errors [5] , the human orthologues of the ␣ 1 and ␤ 1 subunits were initially misinterpreted as ␣ 3 and ␤ 3 subunits [6] . Homology screening yielded two further subunits, consistently designated ␣ 2 and ␤ 2 [7, 8] .
Co-expression revealed that one ␣ and one ␤ subunit is required for the formation of a catalytically active enzyme [9, 10] . The only isoforms of GC that were shown to exist physiologically as NO-stimulated cGMP-forming enzymes are the ␣ 1 ␤ 1 and the ␣ 2 ␤ 1 heterodimers [11] . There is one report on the functional expression of an ␣ 1 ␤ 2 heterodimer [12] which has not been reconfirmed so far. In summary, published data on the ␤ 2 subunit are rare, which may be due to the fact that negative results are often discarded [13] . A frameshift deletion has been shown in the human gene of the ␤ 2 subunit [14] ; the same group reported the rat ␤ 2 subunit to be catalytically active and NOsensitive only when expressed without a different subunit and when measured with manganese as the bivalent cation [15] . Together with data on the quantitative tissue distribution of the ␤ 2 subunit (see below), a physiological role of the ␤ 2 subunit is in doubt. Homodimers of human ␣ 1 and ␤ 1 subunits have been recombinantly expressed and purified but were catalytically inactive [16] .
Domain structure
Each subunit in principle is composed of three parts: a catalytic domain at the C-terminus, a domain commonly referred to as the dimerization domain and an N-terminal regulatory domain involved in haem binding. The C-terminal catalytic domains are conserved in the peptide receptor GCs and the adenylyl cyclases. When expressed as truncated mutants (with the dimerization domains) the catalytic parts exhibit basal cGMP-forming activity, whereas NO stimulation requires intact N-termini [17] . Structure determination of the catalytic core of the structurally related adenylyl cyclases [18, 19] demonstrated an antiparallel orientation of the two catalytic domains with two pockets, each formed by both catalytic domains. In the adenylyl cyclases, one of the pockets represents the catalytic core, and the other one binds the activator forskolin.
Subsequently, three amino acids were identified as determinants of substrate specificity for ATP compared with GTP [20] . The crystal structure also confirmed classical data about the requirement of two bivalent metal ions for catalysis [21, 22] .
Mainly based on studies on the peptide receptor GCs [23] , dimerization is attributed to the conserved central parts of the subunits. Some recent evidence was derived from truncated mutants, where deletion of large N-terminal parts of the ␣ 1 subunit neither prevented dimerization nor abolished basal enzymic activity [24] .
The haem is bound and co-ordinated by the N-terminal parts of the subunits which are therefore commonly designated as regulatory domains. The proximal haem ligand, histidine-105 of the ␤ 1 subunit, is located within this region [25, 26] , and expression of the respective region of the ␤ 1 subunit yielded haem-containing homodimers [27] . The function of the N-terminal part of the ␣ subunits is not clear; one study revealed that the N-terminal part of the ␣ 1 subunit is required for or at least strengthens haem binding [17] , whereas a recent study claimed that deletion of the N-terminal region of the ␣ 1 subunit had no effect on the properties of the enzyme at all [24] . It should be noted that the primary structure of the two ␣ subunits differs considerably in the so-called regulatory region; nevertheless, the regulatory properties of the ␣ 1 ␤ 1 and ␣ 2 ␤ 1 isoforms are indistinguishable [11] .
Tissue distribution
The tissue distribution of the NO receptor has been addressed by a number of techniques. Northern-blot analysis revealed a ubiquitous distribution of the ␣ 1 and ␤ 1 subunits in accordance with the ␣ 1 ␤ 1 isoform as the predominant isoform. The ␣ 2 subunit was solely found in brain, placenta and uterus [28] . In rat brain, a widespread distribution of the ␣ 1 , ␣ 2 and ␤ 1 subunits was demonstrated by reverse transcriptase-PCR and in situ hybridization; some regions predominantly expressed either the ␣ 1 or the ␣ 2 subunit [29] , thereby explaining mismatches between the ␣ 1 and ␤ 1 distribution observed earlier [30] . Recently, Mergia et al. [31] quantitatively assessed the tissue distribution of GC subunits in mice by realtime PCR and Western blots and found the ␣ 2 ␤ 1 isoform to be expressed predominantly in brain. The ␣ 1 ␤ 1 isoform was demonstrated to occur throughout the body with highest levels found in lung. It was speculated that the ␣ 1 ␤ 1 isoform content reflects the degree of vascularization rather than a special role of GC in the respective organ. The ␤ 2 content of the tissues analysed was negligible, again arguing against a relevant physiological role of this subunit.
To summarize, three GC subunits have been shown to exist, enabling the formation of two heterodimeric isoforms: the ␣ 1 ␤ 1 isoform originally demonstrated in lung, which we now know to be the tissue with by far the highest expression, and the ␣ 2 ␤ 1 isoform first identified in placenta [11] , but now assumed to be the neuronal isoform ( [31] and see below).
Subcellular targeting
As the regulatory properties of the two isoforms were indistinguishable [11] the physiological relevance of different isoforms was unclear until the ␣ 2 ␤ 1
Guanylyl cyclase: NO hits its target 53
isoform was demonstrated to be associated with the PDZ domain-containing PSD-95 (post-synaptic density protein-95) [32] . Because the interaction with PSD-95 results in a membrane association of the ␣ 2 ␤ 1 isoform in brain, the designation 'NO-sensitive GC' instead of 'soluble GC' should be used. PSD-95 is a membrane-associated guanylyl kinase and the prototype protein of a family of synaptic scaffolds consisting of three PDZ domains as well as other protein-interaction domains {SH3 (Src homology 3) and guanylyl kinase homology domains; for reviews see [33] [34] [35] }. PDZ domains are molecular adapters (approx. 100 amino acids) that bind to the C-termini of their interaction partners in most cases. PSD-95 is anchored to the post-synaptic membrane [36] and is involved in NMDA (N-methyl-D-aspartate) receptor clustering and formation of signal transduction units ('transducisomes'), where signalling enzymes are brought into close contact. PSD-95 binds to the NMDA receptor NR2B subunit via its first and second PDZ domains [37, 38] and via its second PDZ domain to an internal stretch of the neuronal NO synthase mimicking the conformation of a C-terminal peptide [39, 40] . The ␣ 2 ␤ 1 GC binds to the third PDZ domain of PSD-95 via its C-terminal seven amino acids (FLRETSL-CO 2 H) [32] . The components of the NO/cGMP signalling machinery are gathered closely together, thereby allowing efficient signalling without raising second-messenger concentrations throughout the cell. In the case of the NMDA receptor and NO synthase, it has been shown that the proximity between the NMDA receptor-gated calcium influx and the NO synthase is required for the activation of the NO-generating enzyme, as calcium provided by other sources was not as effective [41] [42] [43] . The respective functional data in support of an association between the ␣ 2 ␤ 1 GC and the NO synthase are still missing. Immunohistochemistry of the CA1 region of the hippocampus revealed a post-synaptic localization of the neuronal NO synthase and a presynaptic signal with antibodies against the ␤ 1 subunit [44] . As this argues against a post-synaptic localization of the ␣ 2 ␤ 1 isoform, one has to take into account that the PDZ domains 1, 2 and 3 are highly conserved between the members of the PSD-95 family, with only a few amino acids differing in the respective regions. Furthermore, as at least SAP97, a member of the PSD-95 family, is clearly located at the presynaptic side as well [45] , one might speculate about a vis-á-vis position of GC and NO synthase with NO as retrograde messenger. However, comprehensive conclusions are impossible until additional immunohistochemical information about the distribution of the three GC subunits in other regions of the brain in conjunction with functional data are available.
Besides the interaction of the ␣ 2 ␤ 1 isoform with PDZ-containing proteins, translocation of the ␣ 1 ␤ 1 isoform to the plasma membrane in response to elevated calcium concentrations has been reported. Furthermore, the membrane-associated enzyme displayed a higher NO sensitivity [46] . The calcium-dependent membrane association has been attributed to an interaction with heat-shock protein 90 [47] but this mechanism awaits confirmation.
Taken together, the available data indicate that the two functionally indistinguishable isoforms of NO-sensitive GC are differentially distributed: the ␣ 1 ␤ 1 isoform appears to be the vascular form of the enzyme, whereas the neuronal ␣ 2 ␤ 1 enzyme is membrane associated in synaptosomes by interacting with PDZ-containing proteins.
NO sensitizers
Within the last years new substances sensitizing GC towards NO have been identified. The benzyl indazole YC-1 [3-(5Ј-hydroxymethyl-2Ј-furyl)-1-benzylindazole] has been shown to be an inhibitor of platelet aggregation [48, 49] and a blood vessel relaxant [50, 51] . An approx. 10-fold activation of GC by YC-1 has been demonstrated [50, 52] . As this type of enzyme activation could not be prevented by NO scavengers, the mechanism is designated as NO-independent. Yet YC-1 has another more impressive effect: YC-1 shifts the NO concentration-response curve to the left by one order of magnitude, indicating sensitization of the enzyme towards the physiological activator NO [52] . Furthermore, YC-1 sensitizes the GC towards CO: in the presence of YC-1, CO leads to as full an activation of the enzyme as NO even though the affinity for CO is still very low, within the high micromolar range. Although YC-1 binds to the haem-depleted enzyme, the presence of the haem group is required for stimulation by YC-1 [53] . The originally observed effect of YC-1 on the maximally NO-stimulated enzyme [52] has been confirmed by some researchers [54, 55] , whereas others found minimal or no effects [56, 57] . This might reflect different qualities of the purified enzymes: the higher the specific activities induced by NO alone, the smaller the effect of YC-1 on the maximally NO-stimulated enzyme. The novel YC-1 analogues developed by pharmaceutical companies as NO sensitizers are summarized in Table 1 . All of them feature essentially the same properties and differ mainly in the EC 50 , which might reflect better solubility of the new compounds.
The binding site of YC-1 and the new analogues is still not clear. Stasch et al. [58] used photoaffinity labelling studies and mapped the binding site to the N-terminus of the ␣ 1 subunits, specifically to two cysteines (Cys-238 and Cys-243). However, an important role of the cysteines in YC-1 binding is unlikely because these residues are not conserved in the ␣ 2 subunit, yet the effects of It should be noted that the key compound of this group, YC-1, not only affects the cGMP-forming GC but also inhibits the cGMP-degrading phosphodiesterase 5 [62] . At least some of the new substances are supposed to be more specific and have been reported to be devoid of a phosphodiesteraseinhibiting effect [58] .
Activation by NO The prosthetic haem group
As stated above, the heterodimeric holoenzyme contains a prosthetic ferrous haem, where NO binds and activates the enzyme up to 200-fold [63] [64] [65] . After some years of debate about the haem stoichiometry (1 haem per heterodimer [63, 64, 66] versus 2 haems per heterodimer [65]), it is now generally accepted that there is one haem per heterodimer [67] . The enzyme features an absorbance spectrum with a peak at 431 nm (Soret band, ⑀Ϸ150 mM Ϫ1 •cm Ϫ1 ) that indicates a five-coordinated ferrous haem iron with a histidine at the fifth co-ordinating position [68] . The His-105 of the ␤ 1 subunit was identified as the proximal haem ligand [25, 26, 69] . Substitution with phenylalanine resulted in a haem-deficient enzyme with intact basal cGMPforming activity [25] ; even after reconstitution with haem the enzyme could not be activated by NO, indicating that the histidine is involved in the transduction of the stimulatory effect of NO [69] . The absence of the His-105 in the ␣ subunits corroborates the haem stoichiometry.
NO binding
It is generally accepted that binding of NO to the haem eventually results in breakage of the histidine-iron bond with the formation of a five-coordinated nitrosyl-haem complex leading to activation of the enzyme. Thereafter, the enzyme features a shifted absorption maximum at 399 nm [63] . The haem precursor protoporphyrin IX that lacks the central iron stimulates the enzyme NO-independently by replacing the haem [70] and mimicking the conformation of NO-bound haem. The release of the histidine-iron bond is required for stimulation of the enzyme, as it is known that binding of CO resulting in an absorbance maximum of 424 nm indicative of a six-coordinated haem iron stimulates the enzyme only 6-fold compared with the 200-fold activation by NO [52, 68] .
The precise mechanisms involved in the formation of the five-coordinated nitrosyl-haem complex are currently being discussed (Figure 1 ). In 1999, Zhao and co-workers [71] showed the intermediate formation of a six-coordinated nitrosyl adduct of GC (with an absorbance maximum at 420 nm) that is converted to the known five-coordinated complex in an NO-dependent manner. This second step in the formation of the final five-coordinated product is at least three orders of magnitude slower than the initial NO-binding step. The sixcoordinated intermediate was not in the activated conformation, supporting the model that scission of the histidine-iron bond is a prerequisite for stimulation of the enzyme. A similar binding model with the formation of a non-stimulated six-coordinated intermediate has also been suggested by Sharma and Magde [72] based on the observation that the formation of the five-coordinated nitrosyl species (399 nm) is not paralleled by the disappearance of the five-coordinated histidine-bound species (431 nm). The requirement of a second NO-binding event to convert the six-coordinated intermediate to the catalytically active fivecoordinated nitrosyl species has been questioned [73] ; however, some assumptions, especially the one that the absorbance at 431 nm solely reflects the amount of five-coordinated NO-free GC, were incorrect [74] .
Although it is not clear whether data from microbial cytochromes cЈ can be applied to GC it is appealing to explain the requirement of a second NO-binding event by the following binding sequence suggested by Lawson and colleagues [75] : NO binds to the distal sixth co-ordinating position; thereafter a second NO molecule can bind to the proximal side, thereby displacing the histidine and finally repelling the NO at the distal face. However, it is not clear whether the haem environments in cytochromes cЈ and GC are comparable; for instance, in cytochromes cЈ the haem is covalently bound by cysteine-thioether linkages. Nevertheless, both haemoproteins share some properties as they both form fivecoordinated NO and six-coordinated CO adducts and do not bind oxygen. Using a dibromodeutero-haem-substituted GC, a stable six-coordinated NO adduct of the enzyme was created. With this six-coordinated NO adduct as well as with the six-coordinated CO adduct of GC it was demonstrated that NO sensitizer YC-1 leads to scission of the histidine-iron bond [57] . In the presence of YC-1, CO is able to stimulate GC as effectively as NO. Hence, it appears tempting to speculate that YC-1 exerts its effects on the NO activation as well as on the CO activation of the enzyme by converting the six-coordinated adducts to the five-coordinated species. In case of CO, this step is a prerequisite for stimulation; in case of NO, YC-1-induced scission of the histidine-iron bond will lead to stimulation of the enzyme at lower concentrations of NO [52] . The formation of a five-coordinated CO adduct in the presence of YC-1 is not yet established clearly. In contrast with the data of Makino et al. [57] , some researchers claimed the CO adduct in the presence of YC-1 to be six-coordinated [59] ; this disagrees with the assumption that cleavage of the histidine-iron bond is a prerequisite for activation of the enzyme. Because of a subtle absorbance shift of the CO adduct upon addition of YC-1 from 424 nm to 420 nm, others discussed weakening of the histidine-iron bond or replacement of the histidine by another base [76] .
Deactivation
Generally, it is assumed that deactivation of GC is triggered mainly by dissociation of NO from the haem group. Other five-coordinated haemoproteins exhibit very slow dissociation rates of NO, resulting in high affinities for NO [77] . For an enzyme involved in a signal-transduction cascade this would raise the problem that an immediate response to a sudden decline in the NO concentration would be impossible. Some studies addressing the issues of dissociation of NO and the resulting deactivation are summarized here. The term 'desensitization' refers to a completely different phenomenon, as it is present in intact cells only and involves mechanisms that are uncharacterized up to now [78] . Dissociation is commonly studied spectrophotometrically after addition of an NO scavenger to the NO-saturated enzyme. Deactivation is measured by monitoring the decline in enzymic activity under these conditions. NO scavengers are required to prevent immediate reassociation of the gaseous ligand with the haem group as, in their absence, the data describe the decay of NO in solution rather than the dissociation from the enzyme or the deactivation [77] .
Kharitonov and colleagues [77] reported a spectrophotometrically determined half-life of the NO-GC complex of 2 min upon addition of oxyhaemoglobin as an NO scavenger. Because deactivation in catalytic assays appeared to be immediate, the substrate MgGTP was included in a later study and a half-life of approx. 5 s was reported in the presence of MgGTP [79] . With the constant levels of GTP in a cell in mind, the apparent effect of the substrate on the dissociation is not assumed to be regulatory; rather it should be considered that studies of the enzyme in the absence of substrate possibly do not describe the enzyme's natural behaviour.
In spectrophotometric experiments, the half-life of 2 min in the absence of substrate was confirmed by the Marletta group [67] . Measurements in the presence of the substrate were hampered by the appearance of a white precipitate.
The deactivation has been assessed in cytosolic preparations of bovine retina, yielding a half-life of 18 s at 20ЊC, which has been extrapolated to a halflife of 5 s at 37ЊC [80] . In intact cerebellar cells, a 25-fold faster deactivation with a half-life of 0.2 s has been reported [81] . Similar results were obtained in human platelets [61] . However, the mechanism of the much faster deactivation in vivo remains unclear.
In an attempt to clarify the mechanism of YC-1 action, the issue of deactivation after NO removal has been addressed in detail with purified GC [61] . In the absence of YC-1, a fast deactivation with a half-life of approx. 4 s was measured, whereas the deactivation in the presence of YC-1 was prolonged 150-fold, yielding a half-life in the range of 10 min. As a mutant was presented that lacked the effects of YC-1 both on the deactivation and on the NO sensitivity, it is conceivable to assume that inhibition of deactivation is the mechanism of YC-1 action. This notion is also in accordance with the abovementioned observations that YC-1 leads to scission of the histidine-iron bond [57] , as destabilization of the bond should result in a slower deactivation.
A new haem-independent activator
In high-throughput screenings, BAY 58-2667 was identified as an NO-independent activator of the NO-sensitive GC. In contrast to the NOsensitizing substances summarized in Table 1 , BAY 58-2667 does not sensitize the enzyme towards NO but activates the enzyme independently of the haem, as it was shown to stimulate the enzyme more effectively if the haem was oxidized or completely absent [82] . The latter suggests either stabilization of the haem-free enzyme or substitution of the haem group as the underlying mechanism of action. However, the occurrence of oxidized or haem-depleted enzyme in vivo has not been demonstrated yet.
Inhibitors
In addition to the non-specific inhibitors Methylene Blue and LY-83583 that have been shown to interfere with NO synthesis [83] or nucleotide-gated ion channels [84] , two substances are known to specifically inhibit the NO-sensitive GC. The quinoxalin derivative ODQ (1H- [1, 2, 4] [85, 86] . The inhibitory effect has been demonstrated in a variety of tissues [85, [87] [88] [89] . ODQ binds in an NO-competitive manner and inhibits NO-stimulated activity, leaving basal enzymic activity unchanged. Oxidation of the haem iron was demonstrated as the underlying mechanism [90, 91] .
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Conclusions and perspective
Although studies during the last few years have unravelled many unexpected properties of the NO-sensitive GC, many aspects of the mechanisms of activation and deactivation are still speculative and await further confirmation. With the NO sensitizers, a new group of substances is emerging that has the potential to improve the currently applied therapy of cardiovascular disorders. Precise information on the mechanism of NO sensitization will greatly improve current knowledge of the NO receptor and will help to elucidate how the NO sensitivity of the enzyme is triggered physiologically. Determination of the enzyme's structure will help us to elucidate how gaseous ligands and the new NO sensitizers exert their effects on the conformation of the enzyme, thereby leading to enhanced formation of the second-messenger molecule, cGMP.
